Drug intelligence / Profile preview

5-imino-4-(2-trifluoromethyl-phenylazo)-5H-pyrazol-3-ylamine

Development stage: Unknown
Modality: Small Molecules

Overview

5-imino-4-(2-trifluoromethyl-phenylazo)-5H-pyrazol-3-ylamine is an experimental small molecule inhibitor of methionine aminopeptidase. It has been studied primarily in biochemical and structural biology contexts as a potent inhibitor of bacterial methionine aminopeptidases, with reported IC50 values in the nanomolar range for Escherichia coli enzyme. The compound is not approved for clinical use and is mainly used as a research tool to study protein processing enzymes[1][6][10].

Other names: 4-{2-[2-(trifluoromethyl)phenyl]hydrazin-1-ylidene}-4,5-dihydro-3H-pyrazole-3,5-diimineN-[(3,5-diiminopyrazol-4-ylidene)amino]-2-(trifluoromethyl)aniline

Targets

METAP1 (Methionine aminopeptidase 1)

Beyond the preview

Go deeper on 5-imino-4-(2-trifluoromethyl-phenylazo)-5H-pyrazol-3-ylamine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 5-imino-4-(2-trifluoromethyl-phenylazo)-5H-pyrazol-3-ylamine.

Explore the full profile